Overview A Multiple Dose Opioid Challenge Study Status: Completed Trial end date: 2016-04-01 Target enrollment: Participant gender: Summary Multi-site, randomized, double-blind, repeat-dose Phase 2 study to evaluate the degree and duration of action of multiple doses of CAM2038 in blocking the effects of hydromorphone in patients with moderate or severe opioid use disorder. Phase: Phase 2 Details Lead Sponsor: Braeburn PharmaceuticalsTreatments: BuprenorphineHydromorphone